FIELD: chemistry.
SUBSTANCE: present invention relates to an atropisomer of an ATM inhibitor of 8-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methyl-1, 3-dihydroimidazo[4,5-c]quinolin-2-one, specifically to a compound of formula Compound 1, or a pharmaceutically acceptable salt thereof. Also disclosed are Compound 1 in a solid anhydrous form and a pharmaceutical composition for treating cancer, containing Compound 1, a pharmaceutically acceptable salt thereof or a solid anhydrous form.
EFFECT: disclosed compound has better inhibiting properties with respect to ATM, and also has better microsomal clearance and low inhibition of phosphodiesterase (PDE) 2A1, as well as PDE4A1A and PDE4E2, and improved solubility in buffer solutions.
5 cl, 52 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOLONYL QUINOLINES AND USE THEREOF AS KINASE ATM INHIBITORS | 2016 |
|
RU2743343C2 |
| METHOD OF PRODUCING CRYSTALLINE FORM OF MNK INHIBITORS | 2019 |
|
RU2821258C2 |
| COMPOUNDS SUITABLE FOR USE AS ATR KINASE INHIBITORS | 2014 |
|
RU2687276C2 |
| METHOD OF PRODUCING ATR KINASE INHIBITORS (EMBODIMENTS) | 2014 |
|
RU2720408C2 |
| COMPOUNDS APPLICABLE AS ATR KINASE INHIBITORS | 2020 |
|
RU2750148C1 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| DUAL ATM AND DNA-PK INHIBITORS FOR ANTITUMOR THERAPY | 2020 |
|
RU2800756C1 |
| COMPOSITIONS AND METHODS OF TREATING ANDROGEN-RECEPTOR-POSITIVE CANCER | 2020 |
|
RU2817802C2 |
| COMBINATION OF PIK3 INHIBITOR AND INHIBITOR C-MET | 2013 |
|
RU2705095C2 |
